Stopped: Withdrawn prior to enrolment after review of updated safety data
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes. All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice. The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Real-world Objective Response Rate (rwORR) stratified by EZH2 mutation status.
Timeframe: Fom first dose to end of study participation, which may range from 1 day to up to 5 years.